Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis

Thorax

Volumn 61, Issue 7, 2006, Pages 604-610

  Molina Molina, M ^a   Serrano Mollar, A ^b   Bulbena, O ^b   Fernandez Zabalegui, L ^b   Closa, D ^b   Marin Arguedas, A ^a   Torrego, A ^a   Mullol, J ^a   Picado, C ^a   Xaubet, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYTOCHROME C OXIDASE; HYDROXYPROLINE; LOSARTAN; MESSENGER RNA; MYELOPEROXIDASE; PROSTAGLANDIN E2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; ENZYME ACTIVITY; HISTOPATHOLOGY; INFLAMMATION; LUNG FIBROSIS; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLEOMYCIN; CYCLOOXYGENASE 2; DINOPROSTONE; LOSARTAN; MALE; PULMONARY FIBROSIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33745817789     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.051946     Document Type: Article

References (39)

1. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
2. Fellrath JM, du Bois RM. Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Clin Exp Med 2003;3:65-83.
3. Pardo A, Selman M. Idiopathic pulmonary Fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 2002;34:1534-8.
4. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
5. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003;201:343-54.
6. Ramos C, Montano M, Garcia-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001;24:591-8.
7. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med J 1998;30(Suppl 1):3-8.
8. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-8.
9. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
10. Kuno A, Yamada T, Masuda K, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003;124:1010-9.
11. Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L156-64.
12. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000;161:1999-2004.
13. Papp M, Li X, Zhuang J, et al. Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 2002;282:L713-8.
14. Borok Z, Gillissen A, Buhl R, et al. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 1991;144:1080-4.
15. Ozaki T, Moriguchi H, Nakamura Y, et al. Regulatory effect of prostaglandin E2 on fibronectin release from human alveolar macrophages. Am Rev Respir Dis 1990;141:965-9.
16. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995;95:1861-8.
17. Keerthisingam CB, Jenkins RG, Harrison NK, et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411-22.
18. Xaubet A, Roca-Ferrer J, Pujols L, et al. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoid Vasc Diffuse Lung Dis 2004;21:35-42.
19. Molina-Molina M, Serrano A, Xaubet A, et al. Evaluation of antifibrotic activity of angiotensin II antagonists (losartan) in bleomycin-induced pulmonary fibrosis in rats (abstract). Am J Respir Crit Care Med, 2004;A862.
20. Molina-Molina M, Serrano A, Xaubet A, et al. Estudio del efecto antifibrótico de los antagonistas de la angiotensina II (losartan) en la fibrosis pulmonar inducida con bleomicina en ratas (abstract). Arch Bronconeumol 2004;40(Suppl 2):P126.
21. Serrano-Mollar A, Closa D, Cortijo J, et al. P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax 2002;57:629-34.
22. Cortijo J, Cerda-Nicolas M, Serrano A, et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J 2001;17:1228-35.
23. Trush MA, Egner PA, Kensler TW. Myeloperoxidase as a biomarker of skin irritation and inflammation. Food Chem Toxicol 1994;32:143-7.
24. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-7.
25. Otsuka M, Takahashi H, Shiratori M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004;59:31-8.
26. Bullock GR, Steyaert I, Bilbe G, et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 2001;115:117-24.
27. Specks U, Martin WJ, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990;141:117-23.
28. Grafe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804-11.
29. Ito H, Takemori K, Suzuki T. Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. J Hypertens 2001;19:591-7.
30. Keogh KA, Standing J, Kane GC, et al. Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2005;25:708-14.
31. Uhal BD, Wang R, Laukka J, et al. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Pharmacol 2003;92:81-7.
32. Renzoni EA, Abraham DJ, Howat S, et al. Gene expression reveals novel TGFβ targets in adult lung fibroblasts. Respir Res 2004;5:24.
33. 2. Trends Immunol 2004;25:40-6.
34. Kohyama T, Ertl RF, Valenti V, et al. Prostaglandin E(2) inhibits fibroblast chemotaxis. Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-63.
35. Fine A, Poliks CF, Donahue LP, et al. The differential effect of prostaglandin E2 on transforming growth factor-beta and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989;264:16988-91.
36. Lama V, Moore BB, Christensen P, et al. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 2002;27:752-8.
37. Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999;103:953-61.
38. Bonner JC, Rice AB, Ingram JL, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 2002;161:459-70.
39. Hodges RJ, Jenkis RG, Wheeler-Jones CP, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E2 production. Am J Pathol 2004;165:1663-76.